Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06288893
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-04
First Post:
2024-02-29
Brief Title:
SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections COVID-19
Sponsor:
JKT Biopharma Co Ltd
Organization:
JKT Biopharma Co Ltd
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Multicenter Phase II Clinical Study to Evaluate the Efficacy Safety and Pharmacokinetics of SHEN211 Tablets in the Treatment of Patients With Mild and Moderate Novel Coronavirus Infection
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Randomized double-blind placebo-controlled multicenter phase II clinical study of SHEN211 tablets
Detailed Description:
A total of 30 patients with mild to moderate novel coronavirus infection COVID-19 were enrolled and randomized in a 21 ratio to the experimental and placebo groups and subjects received 5 days of oral administration of SHEN211 or SHEN211 placebo to assess the effectiveness of SHEN211 tablets in the treatment of mild to moderate COVID-19 patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None